Selank vs Semax: How the Two Russian Neuropeptides Compare in Research (2026)
A research-framed comparison of Selank and Semax — two synthetic neuropeptides from the same Russian research tradition, with different parent molecules, different proposed mechanisms, and different study emphases. Mechanism, not advice.
Selank and Semax are almost always mentioned in the same breath. Both are synthetic neuropeptides, both came out of the same post-Soviet research program, both are studied mostly via intranasal administration, and both occupy the niche "nootropic peptide" shelf in Western research catalogs. That shared origin makes them feel interchangeable. They are not. They descend from different parent molecules, carry different proposed mechanisms, and the published work emphasizes different research questions. This guide compares the two on the dimensions that actually distinguish them. It is a research-use explainer, not advice for human use.
For the standalone compound overviews, see our Selank research guide and Semax research guide. This article focuses on the comparison.
Neither Selank nor Semax is an FDA-approved drug. Every effect described below is drawn from preclinical animal models or limited Russian-language clinical work. Nothing here is a human-use, cognitive-enhancement, or self-administration claim.
Same tradition, different parents
The single most important distinction is genealogical. The two peptides are built from unrelated biological starting points:
- Selank is a stabilized analog of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin G heavy chain with studied immunomodulatory activity. Its sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is the tuftsin fragment plus a Pro-Gly-Pro tail added to resist peptidase degradation.
- Semax is a fragment of ACTH (adrenocorticotropic hormone), specifically the ACTH(4–7) region with a stabilizing Pro-Gly-Pro extension. Its sequence (Met-Glu-His-Phe-Pro-Gly-Pro) descends from a stress-hormone peptide, not an immune fragment.
Both share the same Pro-Gly-Pro stabilization trick — the Russian chemists' signature move for extending neuropeptide half-life — which is part of why they look like siblings. But the active "head" of each molecule comes from a completely different biological system. That is the root of every downstream difference.
Different proposed mechanisms
Because the parents differ, the proposed mechanisms differ too:
| Dimension | Selank | Semax |
|---|---|---|
| Parent molecule | Tuftsin (Ig fragment) | ACTH(4–7) (stress hormone) |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Met-Glu-His-Phe-Pro-Gly-Pro |
| Research emphasis | Anxiolytic, anti-stress, immune | Cognitive, attention, neuroprotection |
| Frequently cited signal | GABA / serotonin modulation | BDNF, neurotrophic pathways |
| Origin lab tradition | Institute of Molecular Genetics (RU) | Institute of Molecular Genetics (RU) |
The Selank literature reports modulation of neurotransmitter systems (GABA, serotonin) and carryover immunomodulatory activity from its tuftsin parent. The Semax literature is most often associated with BDNF (brain-derived neurotrophic factor) and neurotrophic signaling, which is why it is framed as a cognitive and neuroprotection compound rather than an anxiolytic one. These are preclinical associations, not established human mechanisms — but they point the two compounds in genuinely different directions.
Different research questions
The study emphasis follows the mechanism:
- Selank research clusters around anxiolytic and anti-stress models — elevated plus maze, conflict tests, physiological stress responses — plus immunomodulation work inherited from tuftsin. Our companion piece on the anxiolytic research models goes deeper on that side.
- Semax research clusters around cognitive performance, attention, learning tasks, and neuroprotection in injury models, with the BDNF link as a recurring thread. The nootropic research models piece covers that emphasis.
The overlap is real — both touch CNS function and both are sometimes studied for stress-related endpoints — but treating a Selank anxiolytic finding as evidence for Semax's cognitive claims (or vice versa) is exactly the kind of cross-citation that the separate parentage should warn against.
Both literatures are largely Russian-language and largely preclinical. A handful of small clinical studies exist for each, but neither has the large, rigorous Western trials that would settle their human effects. For both compounds, the gap between "studied in rodent models" and "established in humans" is wide — and it is roughly equally wide for both. Neither is the "more proven" choice.
What they share
The similarities are real and worth stating plainly, because they explain why the two are bracketed together:
- Origin — both came from the same Russian neuropeptide program at the Institute of Molecular Genetics.
- Stabilization — both use the Pro-Gly-Pro tail to resist peptidase degradation, a shared design principle.
- Route — both are studied predominantly via intranasal administration in research models, a sensible choice for CNS-targeting peptides.
- Market position — both are niche compounds with narrower US supplier coverage and weaker QC norms than mainstream peptides like BPC-157.
That last point matters for sourcing: niche neuropeptides are exactly where generic COAs and thin documentation are most common.
Why the niche makes sourcing harder for both
Selank and Semax sit in the same sourcing reality: a comparatively narrow US supplier landscape, fewer vendors who have invested in serious QC, and a higher prevalence of generic (non-batch-specific) documentation. For neuropeptide research where the endpoints are subtle, even small purity gaps add noise — so the verification bar is the same for both. Insist on ≥97% HPLC purity, a batch-specific Certificate of Analysis tied to your exact lot, and cold-chain shipping, since both peptides degrade faster once reconstituted. Our guide to reading a peptide COA covers what a defensible document looks like, and the in-catalog reference pages — Selank and Semax — plus where to buy peptides cover compound-specific sourcing.
Both compounds sit in the cognitive research cluster; see the cognitive research goal and the broader peptide catalog for adjacent neuropeptides.
Bottom line
Selank and Semax are siblings by origin and route, not by mechanism. Selank is a stabilized tuftsin analog studied mainly in anxiolytic, anti-stress, and immune models; Semax is a stabilized ACTH fragment studied mainly in cognitive, attention, and neuroprotection models, with a recurring BDNF link. Both rest on largely Russian-language preclinical literature with thin Western clinical investigation, so neither is the "more proven" option — the honest framing for both is promising but unsettled. Read each on its own terms, don't cross-cite their findings, and source both from a verified, well-documented supplier. For the standalone profiles, see the Selank and Semax guides.
For research use only. This content is informational and does not constitute medical or dosing advice. All compounds referenced are for laboratory research use only — not for human consumption.
The top-ranked supplier in our 2026 evaluation
ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.
- Cold-chain shipped
- Batch CoA in every box
- 30-day re-test policy
- 98%+ verified purity
Disclosure: Peptide Research Review maintains affiliate relationships with some of the suppliers we reference. Affiliate status has no influence on our research framing or our blinded, third-party lab evaluations. Read our editorial policy and methodology.
Get the full 38-sample purity report by email.
Eight US suppliers, thirty-eight samples, one blinded analytical lab. Every chromatogram, COA, and supplier score — delivered the moment you subscribe.
PDF delivered instantly. No account required. Unsubscribe anytime.
Selank Anxiolytic Research: GABA, Serotonin & the Anti-Stress Mechanism (2026)
A research-framed look at why Selank is studied as an anxiolytic — the proposed GABAergic and serotonergic modulation, enkephalin stabilization, and what separates established findings from speculation. Research use only.
Semax Nootropic Research: BDNF, Neuroplasticity & the ACTH Connection (2026)
A research-framed deep dive into how Semax is studied as a nootropic — the ACTH(4-10) ancestry, BDNF and NGF modulation, neuroplasticity findings, and what is established versus speculative. Research use only.
Blood-Brain-Barrier Peptide Research: How Neuropeptides Reach the CNS (2026)
A research-framed explainer on why most peptides can't cross the blood-brain barrier, the mechanisms that let some through, and why intranasal delivery dominates CNS neuropeptide research. Research use only.